14097-39-3

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4-Tetrahydro-2-methyl-6-isoquinolinol is used as a potential therapeutic agent for its analgesic and anticonvulsant properties, providing pain relief and seizure control.
Used in Neuroprotective Applications:
1,2,3,4-Tetrahydro-2-methyl-6-isoquinolinol is used as a neuroprotective agent, potentially protecting the nervous system from damage and degeneration.
Used in Research and Development:
1,2,3,4-Tetrahydro-2-methyl-6-isoquinolinol is used as a subject of study in the biosynthesis and metabolism of alkaloids in plants, contributing to the understanding of plant chemistry and the development of new pharmaceuticals.

Upstream product

• 54893-54-8 6‐methoxy‐N‐methyl‐1,2,3,4‐tetrahydroisoquinoline 
• 23824-24-0 N-methyl-4,6-dihydroxy-1,2,3,4-tetrahydroisoquinoline 
• 33543-62-3 2-(3-methoxyphenyl)-N-methylethan-1-amine 
• 23824-19-3 2-methylisoquinolin-6(2H)-one 
• 82-54-2 4-methoxy-6-methyl-5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinolin-5-ol 
• 550-10-7 hydrocotarnine 
• 494-55-3 N-methyl-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 922718-57-8 2-methyl-6-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline 
• 216064-82-3 6-(benzyloxy)-2-methyl-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Oxidative Degradation of 6-Hydroxy-1,2,3,4-tetrahydroisoquinolines and 7-Hydroxy-2-benzazepines. A Novel Route to Heterocyclic Quinones

A novel route toward 4,5-indolequinones and 5,8-quinolinequinones, based on the Fremy's salt promoted oxidative degradation of 6-hydroxy-1,2,3,4-tetrahydroisoquinolines and 7-hydroxy-2-benzazepines, is described.

Synthesis and evaluation of tetrahydroisoquinoline derivatives against Trypanosoma brucei rhodesiense

Human African Trypanosomiasis (HAT) is a neglected tropical disease caused by the parasitic protozoan Trypanosoma brucei (T. b.), and affects communities in sub-Saharan Africa. Previously, analogues of a tetrahydroisoquinoline scaffold were reported as having in vitro activity (IC50 = 0.25–70.5 μM) against T. b. rhodesiense. In this study the synthesis and antitrypanosomal activity of 80 compounds based around a core tetrahydroisoquinoline scaffold are reported. A detailed structure activity relationship was revealed, and five derivatives (two of which have been previously reported) with inhibition of T. b. rhodesiense growth in the sub-micromolar range were identified. Four of these (3c, 12b, 17b and 26a) were also found to have good selectivity over mammalian cells (SI > 50). Calculated logD values and preliminary ADME studies predict that these compounds are likely to have good absorption and metabolic stability, with the ability to passively permeate the blood brain barrier. This makes them excellent leads for a blood-brain barrier permeable antitrypanosomal scaffold.